Literature DB >> 7992250

Evaluation of annexin V as a platelet-directed thrombus targeting agent.

J F Tait1, M D Cerqueira, T A Dewhurst, K Fujikawa, J L Ritchie, J R Stratton.   

Abstract

Annexin V is a human phospholipid binding protein (M(r) 36,000) that binds with high affinity to activated platelets in vitro. We studied the biodistribution and thrombus binding of annexin V in rabbit and swine models of fully occlusive arterial thrombi formed 1-2 h prior to injection of annexin V. Iodinated annexin V was cleared from blood in a rapid early phase (t1/2 = 6.4 min, 76% of radioactivity) and a slower late phase (t1/2 = 71 min, 24% of radioactivity). Organ uptake was highest in the kidney and spleen and lowest in heart and skeletal muscle. Thrombus/blood uptake ratios were (mean +/- SEM): 6.39 +/- 1.80 for rabbit iliac artery, 6.97 +/- 1.45 for swine carotid artery, and 7.68 +/- 1.70 for swine femoral artery (all p values < 0.01 versus control artery); a control protein, ovalbumin, showed an uptake ratio of 0.59 +/- 0.08 in swine femoral artery thrombi. These results indicate that annexin V is useful as an agent for selective targeting of platelet-containing thrombi.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992250     DOI: 10.1016/0049-3848(94)90224-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  17 in total

Review 1.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

Review 2.  Membrane Repair: Mechanisms and Pathophysiology.

Authors:  Sandra T Cooper; Paul L McNeil
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

3.  An αIIbβ3- and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis.

Authors:  Jian Jing; Yanna Sun
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

Review 4.  Molecular imaging of platelet activation in thrombus.

Authors:  François Rouzet; Laure Sarda-Mantel; Jean-Baptiste Michel; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2009-02-18       Impact factor: 5.952

Review 5.  What nuclear cardiology can learn from nuclear oncology.

Authors:  Ismet Sarikaya; Steven M Larson; Alvin Freiman; H William Strauss
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

6.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death.

Authors:  F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; M Darkes; R C Robbins; H T Maecker; H W Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 7.  In vivo detection of apoptotic cell death: a necessary measurement for evaluating therapy for myocarditis, ischemia, and heart failure.

Authors:  F Blankenberg; J Narula; H W Strauss
Journal:  J Nucl Cardiol       Date:  1999 Sep-Oct       Impact factor: 5.952

8.  Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V.

Authors:  Shuo Hu; Dale O Kiesewetter; Lei Zhu; Ning Guo; Haokao Gao; Gang Liu; Naoki Hida; Lixin Lang; Gang Niu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

Review 9.  Emerging diagnostic and therapeutic molecular imaging applications in vascular disease.

Authors:  Luis H Eraso; Muredach P Reilly; Chandra Sehgal; Emile R Mohler
Journal:  Vasc Med       Date:  2011-02-10       Impact factor: 3.239

10.  In vivo dynamic imaging of myocardial cell death using 99mTc-labeled C2A domain of synaptotagmin I in a rat model of ischemia and reperfusion.

Authors:  Zhonglin Liu; Ming Zhao; Xiaoguang Zhu; Lars R Furenlid; Yi-Chun Chen; Harrison H Barrett
Journal:  Nucl Med Biol       Date:  2007-09-19       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.